Financial modelling experts have confirmed the potential impact of daily Aspirin doses on life expectancy and said UK pension liabilities could rise by £100bn. Recent medical reports have confirmed the … Continue reading
By Ralph Savage The UK’s leading insurers can maintain their market-leading dividend payments to shareholders despite tough conditions, analysts at Markit said today. However, in a separate note, Investec maintained … Continue reading
The UK non-life insurance market is facing a range of significant challenges which will make 2012-2013 ‘difficult’ for companies, according to Standard & Poors ratings services. In its latest report … Continue reading
Global property insurance rates continued to firm in the first quarter of 2012, according to a report published today by Marsh. Despite the absence of major natural catastrophes during the … Continue reading
If the six-point plan designed to to tackle rising motor insurance premiums outlined by Prime Minister David Cameron yesterday proves anything, it’s that lobbying this coalition just got tougher.
Before the meeting Downing Street had already made its intentions abundantly clear, by cold shouldering any representatives of the claimant personal injury market and briefing the national, trade and broadcast media that it would be the insurance industry itself who would be trusted to decide what changes are necessary in order to pass on savings to consumers.
FOR THOSE RUNNING brokers and insurance companies in the UK non-life market, 2012 promises to be a challenging year with reputation topping my list of worries for the industry.
Issues ranging from closure of a £500m tax loophole to how major property exposures can be managed once a decades-old pact to insure buildings at risk of flooding comes to an end; these and more will all vie for directors’ attention alongside the day to day running of businesses typically located at the grudge purchase end of the high street.
With concerns both legislative and market-driven requiring considerable thought, here’s my top five insurance industry headscratchers.
Somehow it seems rather curious that the guidelines have been published just before the trial.